Skip to content

Our Product

No Compromises

Ethiqa XR is the only commercial extended-release buprenorphine FDA-Indexed for the control of post-procedural pain in mice, rats, and ferrets.

Ethiqa XR provides up to 72 hours of control of post-procedural pain in mice, rats, and ferrets with just one subcutaneous injection.

Ethiqa XR meets industry guidance, which recognizes the need to reduce the discomfort of animals with effective pain management.

Ethiqa XR is cGMP* compliant and made with pharmaceutical-grade ingredients, which ensures purity and consistency, with no endotoxins, polymers, or additives that can interfere with efficacy or result in unwanted side effects.  Ethiqa XR contains no polymers that can irritate or induce immune responses.

Our extended-release formulation using the Fidelipid LAI technology reduces animal handling, lowering stress levels that can skew research results.

Learn more about strict cGMP practices.

*Current Good Manufacturing Practices regulated by the FDA

A cascade of benefits:

Enhanced Animal Well-being: With fewer injections, animals require less handling, resulting in lower stress levels and improved overall well-being.

Reduced Stress: The reduced frequency of injections directly translates to less stress on the animals, promoting a more comfortable and humane environment.

Efficiency and Safety for Technicians: Fewer injections mean reduced workload and lower risk for technicians, enhancing job safety and efficiency.

Streamlined Administration: Fewer injections contribute to a more efficient administrative process, saving time and resources.

Not Compounded, Not Diluted: ensuring compliance with FDA Guidance for Industry #256. 

An ethical imperative
Many industry organizations, including ACLAM, AALAS, and ASLAP, have developed official position statements recognizing the need for reducing the discomfort of lab animals with effective pain management. Ethiqa XR is an example of our commitment to unique solutions that answer unmet needs in animal health.

Proven long-acting pain relief

Pharmacokinetic parameters of Ethiqa XR were studied in mice, rats, and ferrets.  Buprenorphine plasma concentrations were maintained above established levels for analgesia for up to 72-hours in mice, rats, and ferrets after one subcutaneous injection.

Stress affects laboratory animals’ immune systems, cardiovascular responses, and many other health parameters, which can potentially affect your research results.

Minimal animal handling can reduce elevated stress hormones and help assure the quality of your outcomes. 

Learn more about extended pain relief with Ethiqa XR (please read ISI and full box warning).

Animal welfare protection

Post-procedural pain relief with Ethiqa XR facilitates compliance and comports with oversight agency directives regarding the ethical and scientific importance of research animal welfare.

Learn more about extended pain relief with Ethiqa XR (please read ISI and full box warning).

  • The avoidance and minimization of pain and distress in laboratory animals is an ethical obligation and optimizes scientific data interpretations.
  • Assures more accurate dosing using smaller syringes and needles
  • Provides sufficient analgesia to control post-procedural pain in mice, rats, and ferrets for up to 72 hours with just one subcutaneous injection.  Fewer injections result in less handling and less stress for the research animal. Less stress helps ensure the quality of your research results.

Read guidance about the care of laboratory animals.

We’re committed to leading the industry with quality-driven therapeutics.

Important Safety Information

For Rats, Mice, and Ferrets:

Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.

Do not house rats on wood chip-type bedding after administration of Ethiqa XR. Pica involving wood chip-type bedding can be lethal.

Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR.

The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.

For Humans:
Not for use in humans. Keep out of reach of children and pets.
Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.

Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.

Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with humanskin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.

For more information, consult the Prescribing Information including the Boxed Warning.


Abuse Potential

ETHIQA XR contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ETHIQA XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g., depression).

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ETHIQA XR. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.

Accidental Exposure

Because of the potential for adverse reactions associated with accidental exposure, ETHIQA XR should only be administered by veterinarians, veterinary technicians, or laboratory staff who are trained in the handling of potent opioids. Accidental exposure to ETHIQA XR, especially in children, can result in a fatal overdose of buprenorphine.

Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants

Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

See HUMAN SAFETY WARNINGS for detailed information.